Today: 30 April 2026
Browse Category

NASDAQ:SPRB 6 October 2025 - 19 October 2025

Spruce Biosciences Skyrockets on FDA Breakthrough – Will SPRB’s Rally Last or Fade?

Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough News – Experts Weigh In

Spruce Biosciences shares soared over 1,300% on October 6 after its lead drug for Sanfilippo Syndrome Type B received FDA Breakthrough Therapy status. The company raised $50 million in a private placement at $68 per share. SPRB traded in the mid-$150s on October 19, up from $8 before the announcement. Analyst opinions remain split, with a consensus price target below current levels.
19 October 2025
·
Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough – Inside the Stock Surge, Pipeline & Outlook (Oct 2025)

Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough – Inside the Stock Surge, Pipeline & Outlook (Oct 2025)

Spruce Biosciences shares soared over 1,300% after the FDA granted breakthrough therapy designation to its lead drug for Sanfilippo Syndrome Type B. Trading was repeatedly halted amid a flood of investor interest, including public backing from Martin Shkreli. The company, recently relisted on Nasdaq, faces ongoing financial strain with just $16.4 million in cash and no significant revenue.
7 October 2025
··
Spruce Biosciences Skyrockets on FDA Breakthrough – Will SPRB’s Rally Last or Fade?

Spruce Biosciences Skyrockets on FDA Breakthrough – Will SPRB’s Rally Last or Fade?

Spruce Biosciences shares jumped over 250% intraday on Oct. 6, 2025, after the FDA granted Breakthrough Therapy Designation to its lead drug, tralesinidase alfa, for Sanfilippo Syndrome Type B. The stock rose from around $9 to $31. Spruce regained its Nasdaq listing in September following a reverse split. The company reported $16.4 million in cash as of June 30 and remains unprofitable.
6 October 2025
··

Stock Market Today

  • Canadian National Railway (TSX:CNR) Near Fair Value After Recent Price Rise
    April 30, 2026, 12:19 AM EDT. Canadian National Railway's (TSX:CNR) share price has climbed 4.8% in the past month and 13.7% over the last year. The stock trades around CA$147.91, near its estimated intrinsic value of CA$150.02 from a discounted cash flow (DCF) analysis, suggesting it is fairly valued. Canadian National, a key North American freight infrastructure player, is supported by a robust capital investment program and stable cash flow projections through 2029 and beyond. Despite this, its 13.7% return trails some peers, reflecting ongoing market concerns about rail efficiency, regulation, and cross-border trade impacts. Investors should monitor updates as shifts in factors influencing long-term cash generation could affect valuation.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 30.04.2026

30 April 2026
OCBC will pay a total dividend of S$0.58 per share in May, including a S$0.16 special dividend. UOB declared a final dividend of S$0.71 per share despite lower net interest income. ST Engineering reported higher revenue and profit, with a S$0.23 per share dividend. Jardine Matheson raised its annual dividend 4% to US$2.35 per share, payable mid-May.
Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

30 April 2026
Soluna Holdings filed to register the resale of about 2.46 million common shares, with no proceeds going to the company. The move follows Sazmining’s launch of a 3-megawatt Bitcoin mining operation at Soluna’s Project Dorothy 1B in West Texas. Soluna shares last traded at $1.28, up from a $1.08 Nasdaq sale price on April 28. The registered shares include 2.4 million issuable to YA II PN, LTD. via warrant exercise.
Go toTop